NCT04248127

Brief Summary

A randomized, double-blind, crossover dietary intervention trial will test the effects of 4 weeks of daily honey-flavored yogurt intake on markers of inflammation (Th17 cytokines) and oxidative stress (NOX2, UA, RSNO) and associative changes with microbial derived metabolites (SCFAs, BAs, ellagitannins), metabolism and the fecal microbiome. The above suite of selected markers will capture diet-induced systemic changes in inflammation and oxidative stress, while assessing associated microbial changes.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
3mo left

Started Nov 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress96%
Nov 2021Jul 2026

First Submitted

Initial submission to the registry

November 4, 2019

Completed
3 months until next milestone

First Posted

Study publicly available on registry

January 30, 2020

Completed
1.8 years until next milestone

Study Start

First participant enrolled

November 1, 2021

Completed
4.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 25, 2026

Expected
6 days until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2026

Last Updated

February 10, 2026

Status Verified

February 1, 2026

Enrollment Period

4.7 years

First QC Date

November 4, 2019

Last Update Submit

February 5, 2026

Conditions

Keywords

PhenolicHoneyInflammationYogurtMicrobiome

Outcome Measures

Primary Outcomes (1)

  • Concentration of CD4+ T Helper (TH)17 cytokines

    Cytokines included in the panel are: Il-1b, IL-4, IL-6, IL-10, IL-17a, IL-21, IL-22, IL-23, IL-31, IL-33, IFN-gamma, TNF-alpha, IL-17f.

    4 weeks

Secondary Outcomes (8)

  • Concentration of Secondary bile acids

    4 weeks

  • Concentration of Short chain fatty acids

    4 weeks

  • Concentration of urolithins and other ellagitannin-derived metabolites

    4 weeks

  • Concentration of soluble NADPH oxidase (NOX2)

    4 weeks

  • Concentration of uric acid

    4 weeks

  • +3 more secondary outcomes

Study Arms (2)

Honey sweetened yogurt

EXPERIMENTAL

1 tbsp. of honey in 0.6 cup (150g) of plain yogurt. The participants will be asked to consume 2 morning servings of the yogurt for a total of 2 tbsp. of the assigned honey per day.

Other: Honey sweetened yogurt

Sugar sweetened yogurt

PLACEBO COMPARATOR

Sugar will be added to 0.6 cup (150g) of plain yogurt in an isocaloric amount compared to the honey. The participants will be asked to consume 2 morning servings of the yogurt per day.

Other: Sugar sweetened yogurt

Interventions

2 tbsp. of daily honey intake in 1.2 cups of yogurt per day, split into two equal portions

Honey sweetened yogurt

sugar added, in an isocaloric fashion to the honey, to 1.2 cups of yogurt per day, split into two equal portions

Sugar sweetened yogurt

Eligibility Criteria

Age45 Years - 65 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Postmenopausal female: 45-65 years
  • Women: lack of menses for at least two years.
  • Subject is willing and able to comply with the study protocols.
  • Subject is willing to participate in all study procedures
  • BMI 25.0 - 30.0 kg/m2

You may not qualify if:

  • BMI ≥ 31 kg/m2
  • Food allergies
  • Self-reported use of daily anticoagulation agents including aspirin, NSAIDs
  • Vegan, Vegetarians, food faddists or those consuming a non-traditional diet
  • Use of concentrated food supplements/powders and extracts
  • Fruit consumption \> 2 cups/day
  • Vegetable consumption \>3 cups/day
  • Self-reported restriction of physical activity due to a chronic health condition
  • Self-reported chronic/routine high intensity exercise
  • Self-reported diabetes
  • Blood pressure ≥ 140/90 mm Hg
  • Self-reported renal or liver disease
  • Self-reported heart disease, which includes cardiovascular events and stroke
  • Abnormal Metabolic or CBC panels (laboratory values outside the reference range) if determined to be clinically significant by the study physician.
  • Self-reported cancer within past 5 years
  • +10 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of California, Davis; Department of Nutrition

Davis, California, 95616, United States

RECRUITING

Related Links

MeSH Terms

Conditions

OverweightInflammation

Condition Hierarchy (Ancestors)

OvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsPathologic Processes

Study Officials

  • Carl L Keen, PhD

    University of California, Davis; Department of Nutrition

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Robert R Holt, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
The honey intervention or isocaloric amounts of sugar will be provided in yogurt. The study participant will not be told what sweetener they will be receiving.
Purpose
PREVENTION
Intervention Model
CROSSOVER
Model Details: Randomized single-blind 2-arm crossover trial. Each arm will be 4 weeks in length, with a 4 week washout between arms.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 4, 2019

First Posted

January 30, 2020

Study Start

November 1, 2021

Primary Completion (Estimated)

July 25, 2026

Study Completion (Estimated)

July 31, 2026

Last Updated

February 10, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

Locations